{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:08:41Z","timestamp":1793318921022,"version":"4.5.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,5,29]],"date-time":"2023-05-29T00:00:00Z","timestamp":1685318400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,5,29]],"date-time":"2023-05-29T00:00:00Z","timestamp":1685318400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100005762","name":"National Taiwan University Hospital","doi-asserted-by":"publisher","award":["VN-110-02"],"award-info":[{"award-number":["VN-110-02"]}],"id":[{"id":"10.13039\/501100005762","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005762","name":"National Taiwan University Hospital","doi-asserted-by":"publisher","award":["110-S4952"],"award-info":[{"award-number":["110-S4952"]}],"id":[{"id":"10.13039\/501100005762","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005762","name":"National Taiwan University Hospital","doi-asserted-by":"publisher","award":["110-N01"],"award-info":[{"award-number":["110-N01"]}],"id":[{"id":"10.13039\/501100005762","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005762","name":"National Taiwan University Hospital","doi-asserted-by":"publisher","award":["NTUH110-T20"],"award-info":[{"award-number":["NTUH110-T20"]}],"id":[{"id":"10.13039\/501100005762","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["MOST 109-2326-B-002-012-MY3"],"award-info":[{"award-number":["MOST 109-2326-B-002-012-MY3"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["MOST 110-2326-B-400-004"],"award-info":[{"award-number":["MOST 110-2326-B-400-004"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["MOST 110-2628-B-002-041"],"award-info":[{"award-number":["MOST 110-2628-B-002-041"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1007\/s12072-023-10545-6","type":"journal-article","created":{"date-parts":[[2023,5,29]],"date-time":"2023-05-29T14:02:33Z","timestamp":1685368953000},"page":"1139-1149","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":76,"title":["Distinct effects of hepatic steatosis and metabolic dysfunction on the risk of hepatocellular carcinoma in chronic hepatitis B"],"prefix":"10.1007","volume":"17","author":[{"given":"Shang-Chin","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tung-Hung","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tai-Chung","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Ling","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shih-Jer","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sih-Han","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Ming","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen-Hua","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting-Yuan","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hung-Chih","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Jen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei-Jer","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2442-7952","authenticated-orcid":false,"given":"Jia-Horng","family":"Kao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,29]]},"reference":[{"key":"10545_CR1","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/S2468-1253(19)30039-1","volume":"4","author":"J Li","year":"2019","unstructured":"Li J, Zou B, Yeo YH, Feng Y, Xie X, Lee DH, et al. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999\u20132019: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2019;4:389\u2013398","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10545_CR2","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.jhep.2017.06.003","volume":"67","author":"JG Fan","year":"2017","unstructured":"Fan JG, Kim SU, Wong VW. New trends on obesity and NAFLD in Asia. J Hepatol. 2017;67:862\u2013873","journal-title":"J Hepatol"},{"key":"10545_CR3","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","volume":"15","author":"Z Younossi","year":"2018","unstructured":"Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15:11\u201320","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10545_CR4","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.cgh.2021.05.002","volume":"20","author":"LA Orci","year":"2022","unstructured":"Orci LA, Sanduzzi-Zamparelli M, Caballol B, Sapena V, Colucci N, Torres F, et al. Incidence of hepatocellular carcinoma in patients with nonalcoholic fatty liver disease: a systematic review, meta-analysis, and meta-regression. Clin Gastroenterol Hepatol. 2022;20:283-292.e210","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10545_CR5","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","volume":"73","author":"M Eslam","year":"2020","unstructured":"Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73:202\u2013209","journal-title":"J Hepatol"},{"key":"10545_CR6","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1111\/liv.14548","volume":"40","author":"S Lin","year":"2020","unstructured":"Lin S, Huang J, Wang M, Kumar R, Liu Y, Liu S, et al. Comparison of MAFLD and NAFLD diagnostic criteria in real world. Liver Int. 2020;40:2082\u20132089","journal-title":"Liver Int"},{"key":"10545_CR7","doi-asserted-by":"publisher","first-page":"451","DOI":"10.5009\/gnl20218","volume":"15","author":"SC Huang","year":"2021","unstructured":"Huang SC, Su HJ, Kao JH, Tseng TC, Yang HC, Su TH, et al. Clinical and histologic features of patients with biopsy-proven metabolic dysfunction-associated fatty liver disease. Gut Liver. 2021;15:451\u2013458","journal-title":"Gut Liver"},{"key":"10545_CR8","doi-asserted-by":"publisher","first-page":"2172","DOI":"10.1016\/j.cgh.2021.05.029","volume":"19","author":"VH Nguyen","year":"2021","unstructured":"Nguyen VH, Le MH, Cheung RC, Nguyen MH. Differential clinical characteristics and mortality outcomes in persons with NAFLD and\/or MAFLD. Clin Gastroenterol Hepatol. 2021;19:2172-2181.e2176","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10545_CR9","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1016\/j.jfma.2020.05.027","volume":"119","author":"HJ Su","year":"2020","unstructured":"Su HJ, Kao JH, Tseng TC, Yang HC, Su TH, Chen PJ, et al. Pathologic findings of patients with nonalcoholic fatty liver disease and the impact of concurrent hepatitis B virus infection in Taiwan. J Formos Med Assoc. 2020;119:1476\u20131482","journal-title":"J Formos Med Assoc"},{"key":"10545_CR10","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1111\/liv.15252","volume":"42","author":"M Yang","year":"2022","unstructured":"Yang M, Wei L. Impact of NAFLD on the outcome of patients with chronic hepatitis B in Asia. Liver Int. 2022;42:1981\u20131990","journal-title":"Liver Int"},{"key":"10545_CR11","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1016\/j.jfma.2022.07.013","volume":"121","author":"SC Huang","year":"2022","unstructured":"Huang SC, Kao JH. Metabolic dysfunction-associated fatty liver disease and chronic hepatitis B. J Formos Med Assoc. 2022;121:2148\u20132151","journal-title":"J Formos Med Assoc"},{"key":"10545_CR12","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1002\/hep.28917","volume":"65","author":"EJ Joo","year":"2017","unstructured":"Joo EJ, Chang Y, Yeom JS, Ryu S. Hepatitis B virus infection and decreased risk of nonalcoholic fatty liver disease: a cohort study. Hepatology. 2017;65:828\u2013835","journal-title":"Hepatology"},{"key":"10545_CR13","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1111\/j.1440-1746.2008.05531.x","volume":"23","author":"JP Shi","year":"2008","unstructured":"Shi JP, Fan JG, Wu R, Gao XQ, Zhang L, Wang H, et al. Prevalence and risk factors of hepatic steatosis and its impact on liver injury in Chinese patients with chronic hepatitis B infection. J Gastroenterol Hepatol. 2008;23:1419\u20131425","journal-title":"J Gastroenterol Hepatol"},{"key":"10545_CR14","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1007\/s12072-021-10218-2","volume":"15","author":"LY Mak","year":"2021","unstructured":"Mak LY, Hui RW, Fung J, Liu F, Wong DK, Li B, et al. Reduced hepatic steatosis is associated with higher risk of hepatocellular carcinoma in chronic hepatitis B infection. Hepatol Int. 2021;15:901\u2013911","journal-title":"Hepatol Int"},{"key":"10545_CR15","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1007\/s12072-021-10205-7","volume":"15","author":"JH Oh","year":"2021","unstructured":"Oh JH, Lee HW, Sinn DH, Park JY, Kim BK, Kim SU, et al. Controlled attenuation parameter value and the risk of hepatocellular carcinoma in chronic hepatitis B patients under antiviral therapy. Hepatol Int. 2021;15:892\u2013900","journal-title":"Hepatol Int"},{"key":"10545_CR16","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1111\/apt.16595","volume":"54","author":"Q Zheng","year":"2021","unstructured":"Zheng Q, Zou B, Wu Y, Yeo Y, Wu H, Stave CD, et al. Systematic review with meta-analysis: prevalence of hepatic steatosis, fibrosis and associated factors in chronic hepatitis B. Aliment Pharmacol Ther. 2021;54:1100\u20131109","journal-title":"Aliment Pharmacol Ther"},{"key":"10545_CR17","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1111\/jgh.13536","volume":"32","author":"AW Chan","year":"2017","unstructured":"Chan AW, Wong GL, Chan HY, Tong JH, Yu YH, Choi PC, et al. Concurrent fatty liver increases risk of hepatocellular carcinoma among patients with chronic hepatitis B. J Gastroenterol Hepatol. 2017;32:667\u2013676","journal-title":"J Gastroenterol Hepatol"},{"key":"10545_CR18","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1002\/hep.30857","volume":"71","author":"HSJ Choi","year":"2020","unstructured":"Choi HSJ, Brouwer WP, Zanjir WMR, de Man RA, Feld JJ, Hansen BE, et al. Nonalcoholic steatohepatitis is associated with liver-related outcomes and all-cause mortality in chronic hepatitis B. Hepatology. 2020;71:539\u2013548","journal-title":"Hepatology"},{"key":"10545_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2021.100350","volume":"3","author":"LA van Kleef","year":"2021","unstructured":"van Kleef LA, Choi HSJ, Brouwer WP, Hansen BE, Patel K, de Man RA, et al. Metabolic dysfunction-associated fatty liver disease increases risk of adverse outcomes in patients with chronic hepatitis B. JHEP Rep. 2021;3: 100350","journal-title":"JHEP Rep"},{"key":"10545_CR20","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1016\/j.jfma.2021.12.024","volume":"121","author":"YC Lee","year":"2022","unstructured":"Lee YC, Chao YT, Lin PJ, Yang YY, Yang YC, Chu CC, et al. Quality assurance of integrative big data for medical research within a multihospital system. J Formos Med Assoc. 2022;121:1728\u20131738","journal-title":"J Formos Med Assoc"},{"key":"10545_CR21","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.7863\/jum.2002.21.9.1023","volume":"21","author":"H Tchelepi","year":"2002","unstructured":"Tchelepi H, Ralls PW, Radin R, Grant E. Sonography of diffuse liver disease. J Ultrasound Med. 2002;21:1023\u20131032 (quiz 1033-1024)","journal-title":"J Ultrasound Med"},{"key":"10545_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","volume":"10","author":"SK Sarin","year":"2016","unstructured":"Sarin SK, Kumar M, Lau GK, Abbas Z, Chan HL, Chen CJ, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016;10:1\u201398","journal-title":"Hepatol Int"},{"issue":"67","key":"10545_CR23","first-page":"370","volume":"2017","author":"EASL","year":"2017","unstructured":"EASL. Clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;2017(67):370\u2013398","journal-title":"J Hepatol"},{"key":"10545_CR24","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/hep.29800","volume":"67","author":"NA Terrault","year":"2018","unstructured":"Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67:1560\u20131599","journal-title":"Hepatology"},{"key":"10545_CR25","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1148\/radiol.2018171116","volume":"288","author":"TH Su","year":"2018","unstructured":"Su TH, Liao CH, Liu CH, Huang KW, Tseng TC, Yang HC, et al. Acoustic radiation force impulse US imaging: liver stiffness in patients with chronic hepatitis B with and without antiviral therapy. Radiology. 2018;288:293\u2013299","journal-title":"Radiology"},{"key":"10545_CR26","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1002\/hep.24199","volume":"53","author":"J Bruix","year":"2011","unstructured":"Bruix J, Sherman M. American association for the study of liver D: management of hepatocellular carcinoma: an update. Hepatology. 2011;53:1020\u20131022","journal-title":"Hepatology"},{"key":"10545_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v045.i03","volume":"45","author":"S van Buuren","year":"2011","unstructured":"van Buuren S, Groothuis-Oudshoorn K. Mice: multivariate imputation by chained equations in R. J Stat Softw. 2011;45:1\u201367","journal-title":"J Stat Softw"},{"key":"10545_CR28","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1002\/sim.5984","volume":"33","author":"PC Austin","year":"2014","unstructured":"Austin PC. The use of propensity score methods with survival or time-to-event outcomes: reporting measures of effect similar to those used in randomized experiments. Stat Med. 2014;33:1242\u20131258","journal-title":"Stat Med"},{"key":"10545_CR29","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/jvh.12766","volume":"25","author":"RWH Hui","year":"2018","unstructured":"Hui RWH, Seto WK, Cheung KS, Mak LY, Liu KSH, Fung J, et al. Inverse relationship between hepatic steatosis and hepatitis B viremia: results of a large case-control study. J Viral Hepat. 2018;25:97\u2013104","journal-title":"J Viral Hepat"},{"key":"10545_CR30","doi-asserted-by":"publisher","first-page":"2571","DOI":"10.1007\/s10620-014-3180-9","volume":"59","author":"MM Wang","year":"2014","unstructured":"Wang MM, Wang GS, Shen F, Chen GY, Pan Q, Fan JG. Hepatic steatosis is highly prevalent in hepatitis B patients and negatively associated with virological factors. Dig Dis Sci. 2014;59:2571\u20132579","journal-title":"Dig Dis Sci"},{"key":"10545_CR31","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1016\/j.jfma.2021.10.014","volume":"121","author":"MW Yu","year":"2022","unstructured":"Yu MW, Lin CL, Liu CJ, Huang YW, Hu JT, Wu WJ, et al. Hepatic steatosis and development of type 2 diabetes: impact of chronic hepatitis B and viral specific factors. J Formos Med Assoc. 2022;121:1478\u20131487","journal-title":"J Formos Med Assoc"},{"key":"10545_CR32","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1007\/s12072-018-9877-7","volume":"12","author":"D Hu","year":"2018","unstructured":"Hu D, Wang H, Wang H, Wang Y, Wan X, Yan W, et al. Non-alcoholic hepatic steatosis attenuates hepatitis B virus replication in an HBV-immunocompetent mouse model. Hepatol Int. 2018;12:438\u2013446","journal-title":"Hepatol Int"},{"key":"10545_CR33","doi-asserted-by":"publisher","first-page":"2481","DOI":"10.1007\/s11010-021-04143-z","volume":"477","author":"Q Liu","year":"2022","unstructured":"Liu Q, Mu M, Chen H, Zhang G, Yang Y, Chu J, et al. Hepatocyte steatosis inhibits hepatitis B virus secretion via induction of endoplasmic reticulum stress. Mol Cell Biochem. 2022;477:2481\u20132491","journal-title":"Mol Cell Biochem"},{"key":"10545_CR34","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1038\/ajg.2009.560","volume":"105","author":"VW Wong","year":"2010","unstructured":"Wong VW, Wong GL, Yu J, Choi PC, Chan AW, Chan HY, et al. Interaction of adipokines and hepatitis B virus on histological liver injury in the Chinese. Am J Gastroenterol. 2010;105:132\u2013138","journal-title":"Am J Gastroenterol"},{"key":"10545_CR35","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.virol.2010.10.024","volume":"409","author":"S Yoon","year":"2011","unstructured":"Yoon S, Jung J, Kim T, Park S, Chwae YJ, Shin HJ, et al. Adiponectin, a downstream target gene of peroxisome proliferator-activated receptor \u03b3, controls hepatitis B virus replication. Virology. 2011;409:290\u2013298","journal-title":"Virology"},{"key":"10545_CR36","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.cgh.2017.09.044","volume":"16","author":"WK Seto","year":"2018","unstructured":"Seto WK, Hui RWH, Mak LY, Fung J, Cheung KS, Liu KSH, et al. Association between hepatic steatosis, measured by controlled attenuation parameter, and fibrosis burden in chronic hepatitis B. Clin Gastroenterol Hepatol. 2018;16:575-583.e572","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10545_CR37","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1016\/j.jhep.2020.05.040","volume":"73","author":"LY Mak","year":"2020","unstructured":"Mak LY, Hui RW, Fung J, Liu F, Wong DK, Cheung KS, et al. Diverse effects of hepatic steatosis on fibrosis progression and functional cure in virologically quiescent chronic hepatitis B. J Hepatol. 2020;73:800\u2013806","journal-title":"J Hepatol"},{"issue":"2","key":"10545_CR38","doi-asserted-by":"publisher","first-page":"320","DOI":"10.3350\/cmh.2022.0422","volume":"29","author":"SC Huang","year":"2023","unstructured":"Huang SC, Liu CJ. Chronic hepatitis B with concurrent metabolic dysfunction-associated fatty liver disease: challenges and perspectives. Clin Mol Hepatol. 2023;29(2):320\u2013331","journal-title":"Clin Mol Hepatol"},{"key":"10545_CR39","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.1002\/hep.26072","volume":"57","author":"D van der Poorten","year":"2013","unstructured":"van der Poorten D, Samer CF, Ramezani-Moghadam M, Coulter S, Kacevska M, Schrijnders D, et al. Hepatic fat loss in advanced nonalcoholic steatohepatitis: are alterations in serum adiponectin the cause? Hepatology. 2013;57:2180\u20132188","journal-title":"Hepatology"},{"key":"10545_CR40","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1053\/j.gastro.2018.08.024","volume":"155","author":"F Kanwal","year":"2018","unstructured":"Kanwal F, Kramer JR, Mapakshi S, Natarajan Y, Chayanupatkul M, Richardson PA, et al. Risk of hepatocellular cancer in patients with non-alcoholic fatty liver disease. Gastroenterology. 2018;155:1828-1837.e1822","journal-title":"Gastroenterology"},{"key":"10545_CR41","doi-asserted-by":"publisher","first-page":"5576","DOI":"10.1200\/JCO.2008.16.1075","volume":"26","author":"MW Yu","year":"2008","unstructured":"Yu MW, Shih WL, Lin CL, Liu CJ, Jian JW, Tsai KS, et al. Body-mass index and progression of hepatitis B: a population-based cohort study in men. J Clin Oncol. 2008;26:5576\u20135582","journal-title":"J Clin Oncol"},{"key":"10545_CR42","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1136\/gut.2004.052167","volume":"54","author":"JA Davila","year":"2005","unstructured":"Davila JA, Morgan RO, Shaib Y, McGlynn KA, El-Serag HB. Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study. Gut. 2005;54:533\u2013539","journal-title":"Gut"},{"key":"10545_CR43","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1053\/j.gastro.2008.03.073","volume":"135","author":"CL Chen","year":"2008","unstructured":"Chen CL, Yang HI, Yang WS, Liu CJ, Chen PJ, You SL, et al. Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B\/C infection: a follow-up study in Taiwan. Gastroenterology. 2008;135:111\u2013121","journal-title":"Gastroenterology"},{"key":"10545_CR44","doi-asserted-by":"publisher","first-page":"301","DOI":"10.2147\/JHC.S355540","volume":"9","author":"RC Hsueh","year":"2022","unstructured":"Hsueh RC, Wu WJ, Lin CL, Liu CJ, Huang YW, Hu JT, et al. Impact of PNPLA3 p.I148M and hepatic steatosis on long-term outcomes for hepatocellular carcinoma and HBsAg seroclearance in chronic hepatitis B. J Hepatocell Carcinoma. 2022;9:301\u2013313","journal-title":"J Hepatocell Carcinoma"},{"key":"10545_CR45","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1093\/infdis\/jiaa739","volume":"224","author":"J Li","year":"2021","unstructured":"Li J, Yang HI, Yeh ML, Le MH, Le AK, Yeo YH, et al. Association between fatty liver and cirrhosis, hepatocellular carcinoma, and hepatitis B surface antigen seroclearance in chronic hepatitis B. J Infect Dis. 2021;224:294\u2013302","journal-title":"J Infect Dis"},{"key":"10545_CR46","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1111\/liv.13644","volume":"38","author":"GY Minuk","year":"2018","unstructured":"Minuk GY, Iliant V, Zhou N, Kaita KD, Wong SG, Peretz D, et al. Concomitant nonalcoholic fatty liver disease does not alter the activity, severity or course of primary biliary cholangitis. Liver Int. 2018;38:1110\u20131116","journal-title":"Liver Int"},{"key":"10545_CR47","doi-asserted-by":"publisher","first-page":"2710","DOI":"10.1007\/s10620-016-4213-3","volume":"61","author":"J De Luca-Johnson","year":"2016","unstructured":"De Luca-Johnson J, Wangensteen KJ, Hanson J, Krawitt E, Wilcox R. Natural history of patients presenting with autoimmune hepatitis and coincident nonalcoholic fatty liver disease. Dig Dis Sci. 2016;61:2710\u20132720","journal-title":"Dig Dis Sci"}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-023-10545-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12072-023-10545-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-023-10545-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T06:42:44Z","timestamp":1719470564000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12072-023-10545-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,29]]},"references-count":47,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["10545"],"URL":"https:\/\/doi.org\/10.1007\/s12072-023-10545-6","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"value":"1936-0533","type":"print"},{"value":"1936-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,29]]},"assertion":[{"value":"24 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"T-HS received a research Grant from Gilead Sciences, and was on speaker\u2019s bureaus for Abbvie, Bayer, Bristol-Myers Squibb, Gilead Sciences, Merck Sharp and Dohme, and Takeda. J-HK has served as a consultant for Abbvie, Abbott, Gilead Sciences, Roche, and Sysmex and on speaker\u2019s bureaus for Abbvie, Bristol-Myers Squibb, Gilead Sciences, Merck Sharp, and Dohme, and Sysmex. S-CH, T-CT, C-LC, S-JH, S-HL, C-MH, C-HL, T-YL, H-CY, C-JL, P-JC declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the Institutional Review Board of National Taiwan University Hospital (202104086RIND) and conformed to the ethical principles for medical research involving human subjects of the Declaration of Helsinki updated in 2013. The informed consent was waived because this is a retrospective study conducted by a review of medical records only.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}